Neue genetische Tests und ihr Nutzen in der Krebsvorsorge

Translated title of the contribution: New genetic tests and their clinical utility for cancer screening

Nicole M. Probst-Hensch, Angela Brand

Research output: Contribution to journalArticle

Abstract

The promises resulting from the decoding of the human genome have not been fulfilled to the extent as expected. At the same time it is fair to say that the results of recent genetic research have not been useless. In the area of familial cancer the clinical benefit of genetic testing for healthy family members is very convincing, where the risk of disease can be reduced substantially through preventive interventions. For example, prophylactic mastectomy and premenopausal ovariectomy can reduce the cancer risk in carriers of BRCA1 and BRCA2 mutations dramatically. In recent years, the research has moved towards the decoding of the genetic causes of sporadic cancers as well. Genome-wide and hypothesis-free association studies have linked different chromosome regions to cancer. By this, new insights into disease mechanisms could be gained, an important requirement for the development of diagnostics and drugs. However, what is missing is the evidence that the associated SNPs (Single Nucleotide Polymorphisms) could be useful for individual risk calculation or for stratification of the population into groups with different preventive or screening needs.

Original languageGerman
Pages (from-to)251-254
Number of pages4
JournalTherapeutische Umschau
Volume70
Issue number4
DOIs
Publication statusPublished - 04-2013

Fingerprint

Early Detection of Cancer
Neoplasms
Free Association
Genetic Research
Genetic Testing
Ovariectomy
Human Genome
Population Groups
Single Nucleotide Polymorphism
Chromosomes
Genome
Mutation
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Probst-Hensch, Nicole M. ; Brand, Angela. / Neue genetische Tests und ihr Nutzen in der Krebsvorsorge. In: Therapeutische Umschau. 2013 ; Vol. 70, No. 4. pp. 251-254.
@article{4eca565301a940bcaf88626d49bb9567,
title = "Neue genetische Tests und ihr Nutzen in der Krebsvorsorge",
abstract = "The promises resulting from the decoding of the human genome have not been fulfilled to the extent as expected. At the same time it is fair to say that the results of recent genetic research have not been useless. In the area of familial cancer the clinical benefit of genetic testing for healthy family members is very convincing, where the risk of disease can be reduced substantially through preventive interventions. For example, prophylactic mastectomy and premenopausal ovariectomy can reduce the cancer risk in carriers of BRCA1 and BRCA2 mutations dramatically. In recent years, the research has moved towards the decoding of the genetic causes of sporadic cancers as well. Genome-wide and hypothesis-free association studies have linked different chromosome regions to cancer. By this, new insights into disease mechanisms could be gained, an important requirement for the development of diagnostics and drugs. However, what is missing is the evidence that the associated SNPs (Single Nucleotide Polymorphisms) could be useful for individual risk calculation or for stratification of the population into groups with different preventive or screening needs.",
author = "Probst-Hensch, {Nicole M.} and Angela Brand",
year = "2013",
month = "4",
doi = "10.1024/0040-5930/a000397",
language = "German",
volume = "70",
pages = "251--254",
journal = "Therapeutische Umschau. Revue therapeutique",
issn = "0040-5930",
publisher = "Verlag Hans Huber",
number = "4",

}

Neue genetische Tests und ihr Nutzen in der Krebsvorsorge. / Probst-Hensch, Nicole M.; Brand, Angela.

In: Therapeutische Umschau, Vol. 70, No. 4, 04.2013, p. 251-254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neue genetische Tests und ihr Nutzen in der Krebsvorsorge

AU - Probst-Hensch, Nicole M.

AU - Brand, Angela

PY - 2013/4

Y1 - 2013/4

N2 - The promises resulting from the decoding of the human genome have not been fulfilled to the extent as expected. At the same time it is fair to say that the results of recent genetic research have not been useless. In the area of familial cancer the clinical benefit of genetic testing for healthy family members is very convincing, where the risk of disease can be reduced substantially through preventive interventions. For example, prophylactic mastectomy and premenopausal ovariectomy can reduce the cancer risk in carriers of BRCA1 and BRCA2 mutations dramatically. In recent years, the research has moved towards the decoding of the genetic causes of sporadic cancers as well. Genome-wide and hypothesis-free association studies have linked different chromosome regions to cancer. By this, new insights into disease mechanisms could be gained, an important requirement for the development of diagnostics and drugs. However, what is missing is the evidence that the associated SNPs (Single Nucleotide Polymorphisms) could be useful for individual risk calculation or for stratification of the population into groups with different preventive or screening needs.

AB - The promises resulting from the decoding of the human genome have not been fulfilled to the extent as expected. At the same time it is fair to say that the results of recent genetic research have not been useless. In the area of familial cancer the clinical benefit of genetic testing for healthy family members is very convincing, where the risk of disease can be reduced substantially through preventive interventions. For example, prophylactic mastectomy and premenopausal ovariectomy can reduce the cancer risk in carriers of BRCA1 and BRCA2 mutations dramatically. In recent years, the research has moved towards the decoding of the genetic causes of sporadic cancers as well. Genome-wide and hypothesis-free association studies have linked different chromosome regions to cancer. By this, new insights into disease mechanisms could be gained, an important requirement for the development of diagnostics and drugs. However, what is missing is the evidence that the associated SNPs (Single Nucleotide Polymorphisms) could be useful for individual risk calculation or for stratification of the population into groups with different preventive or screening needs.

UR - http://www.scopus.com/inward/record.url?scp=84875692505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875692505&partnerID=8YFLogxK

U2 - 10.1024/0040-5930/a000397

DO - 10.1024/0040-5930/a000397

M3 - Article

VL - 70

SP - 251

EP - 254

JO - Therapeutische Umschau. Revue therapeutique

JF - Therapeutische Umschau. Revue therapeutique

SN - 0040-5930

IS - 4

ER -